Overweight or Obesity
142
36
52
60
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Research Maturity
60 completed trials (42% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
1.4%
2 terminated out of 142 trials
96.8%
+10.3% vs benchmark
13%
19 trials in Phase 3/4
13%
8 of 60 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 60 completed trials
Clinical Trials (142)
Development of PI-ML Algorithm for Prediction of the Real-time Risk for Developing Pre-diabetes
A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight
Acute Impact of Whey Protein-enriched Milk Fat Globule Membrane Supplementation on Postprandial Markers of Heart and Brain Health
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in Healthy Subjects
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
A Virtual Cardiometabolic Health Program for African Immigrants: The Afro-DPP Program
PA Moves Trial - Patient Participants
Effect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study)
A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight
A Study of LY4064912 in Healthy Participants and With Overweight or Obesity
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
A Single Ascending Dose Study of SYH2082 Injection in Healthy Participants
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight
Effect of the Thrive AI Health App on Lifestyle Behaviors and Quality of Life
Berries, Inflammation, and Gut Microbiome
Indigenous Supported Agriculture "Go Healthy"